The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to alixorexton, Alkermes’ investigational oral selective orexin 2 receptor agonist, for the treatment of narcolepsy type 1 (NT1). This designation is based on a robust data package from phase 1 and phase 2 studies, including Vibrance-1, and is intended to expedite the development and review of alixorexton given the serious unmet medical need in NT1.

In Vibrance-1, a randomized, placebo-controlled phase 2 trial involving 92 NT1 patients, alixorexton achieved statistically significant and dose-dependent improvements from baseline on the Maintenance of Wakefulness Test (MWT) across all doses tested. The trial demonstrated clinically meaningful gains in wakefulness compared to placebo, and alixorexton was generally well tolerated with no new safety signals reported.

Building on Breakthrough Therapy status, Alkermes intends to launch a global phase 3 program for alixorexton in the first quarter of 2026. The company’s development plan includes pivotal studies in NT1, with potential expansion into narcolepsy type 2 and idiopathic hypersomnia, aligning with the program’s goal to establish a differentiated, once-daily oral therapy targeting the orexin pathway.

Alkermes, a mid-cap biopharmaceutical firm headquartered in Ireland with R&D operations in Massachusetts and manufacturing in Ohio, already commercializes products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder. Breakthrough Therapy designation reduces regulatory risk and may accelerate time to market for alixorexton, potentially transforming treatment standards in central disorders of hypersomnolence and supporting long-term growth prospects for Alkermes’ neuroscience pipeline.